Pay in 4 interest-free payments of $50.00 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
differentiation
8±1 nM and 198±7 nM
is a phosphodiesterase inhibitor selective for the PDE10A subtype
Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr
2-d][1]benzazepin-6(5H)-one
Pasireotide side differentiationPasireotide, also known as SOM230, is an orphan drug approved for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. It was developed by Novartis. Pasireotide is a somatostatin analog with a 40 fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs. Product information CAS Number: 396091 73 9 Molecular Weight: 1047. 21 Formula: C58H66N10O9 Synonym: SOM 230 Signifor SOM 320